By Fineline Cube 
US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK PsA-1 study, assessing Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) who had not previously received biologic disease-modifying antirheumatic drugs (bDMARDs).
Clinical Trial Results
The study met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with deucravacitinib achieved ACR20 at Week 16 compared to placebo (54.2% vs. 34.1%; p<0.0001). This result underscores the drug’s potential to improve outcomes for PsA patients.
Safety Profile
The safety profile of deucravacitinib was consistent with previously reported data during the 16-week treatment period, reinforcing its favorable risk-benefit profile.
Mechanism of Action
Deucravacitinib is an oral, selective TYK2 inhibitor that achieves allosteric inhibition of TYK2 without affecting JAK1, JAK2, or JAK3. This unique mechanism sets it apart in the treatment landscape for autoimmune diseases.-Fineline Info & Tech